The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The potential of mitapivat and other pyruvate kinase activators in SCD
Enrico Novelli, MD, MS, University of Pittsburgh, Pittsburgh, PA, discusses the development of mitapivat, a drug approved for pyruvate kinase deficiency, which shows promise for treating sickle cell disease (SCD). Although not yet approved for SCD, Dr Novelli highlights that both first- and second-generation pyruvate kinase activators have demonstrated an encouraging ability to increase hemoglobin and reduce hemolysis and will hopefully also lead to improvements in vaso-occlusive episodes and disease-related complications. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisor/consultant for Novo Nordisk, Chiesi Pharmaceuticals and Shield Therapeutics.
